EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array–based cytokine profiling

Rochelle Wickramasekara, Valerie Jones, Yating Zhao, Shuhong Luo, Guogui Sun, Ruo-Pan Huang

Drug Resistance Updates · 2026-05 · 86 · 101378

DOI: 10.1016/j.drup.2026.101378 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026-05. Verfasst von Rochelle Wickramasekara und 5 weiteren Autor:innen. Beteiligte Einrichtung: RayBiotech Life Inc., Peachtree Corners, Georgia 30097, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Cytokines, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Therapy resistance remains a major obstacle in the treatment of solid tumors and accounts for most cancer-related deaths. While tumor-intrinsic mechanisms have been well-studied, the tumor microenvironment (TME) is now recognized as a major driver of resistance through non-genetic, cell-extrinsic signaling. Stromal and immune cells-including fibroblasts, macrophages, endothelial cells, and regulatory immune cells-interact with cancer cells via cytokine signaling, direct contact, and extracellular matrix (ECM) remodeling to promote survival, immune evasion, and therapeutic adaptation. OBJECTIVE: This review examines cytokine-mediated signaling mechanisms within the TME that contribute to resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy, drawing on studies with a specific focus on antibody array-based multiplex proteomic profiling. RESULTS: Across multiple tumor types, molecular profiling studies have identified recurrent cytokine and growth factor signaling programs that drive therapy resistance through paracrine and autocrine mechanisms. Key pathways include IL-6/STAT3, CXCL12/CXCR4, and HGF/c-MET among others, through which stromal and immune cells support tumor survival, immune suppression, and therapy evasion. These findings demonstrate that cytokine-mediated resistance mechanisms differ across therapeutic modalities and cellular contexts. Clinical studies targeting these pathways further illustrate how biological context and pathway redundancy influence therapeutic response. CONCLUSION: Cytokine-driven signaling within the TME plays a central role in therapy resistance. Protein profiling studies have contributed mechanistic insight into these interactions and helped define resistance-associated pathways across treatment settings. Ongoing clinical studies will determine how targeting these pathways can be most effectively applied to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentCytokinesDrug Resistance, NeoplasmNeoplasmsAntineoplastic AgentsHumansSignal TransductionProteomicsAnimalsProtein Array AnalysisImmunotherapy

Stichwörter der Autor:innen

Antibody arrayCancer therapy resistanceCytokinesImmune suppressionImmunotherapy resistanceMultiplexProteomic arrayProteomicsStromal cellsTumor microenvironment

Substanzen

CytokinesAntineoplastic Agents

Autor:innen und Institutionen

  • RayBiotech Life Inc., Peachtree Corners, Georgia 30097, USA.
  • Department of Breast Center, Affiliated Hospital of North China University of Science and Technology, No. 73 Jianshe South Road, Lubei District, Tangshan City, Hebei Province 063210, China.
  • RayBiotech Life Inc., Peachtree Corners, Georgia 30097, USA; RayBiotech Guangzhou Co. Ltd., Guangzhou, Guangdong 510000, China; South China Biochip Research Center, No. 79 Ruihe Road, Huangpu District, Guangzhou, Guangd…
  • Affiliated Hospital of North China University of Science and Technology, No. 73 Jianshe South Road, Lubei District, Tangshan City, Hebei Province 063210, China. Electronic address: guogui_sun2021@sina.com.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Wickramasekara, R., Jones, V., Zhao, Y., Luo, S., Sun, G., & Huang, R. P. (2026). Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array–based cytokine profiling. Drug Resistance Updates, 86, 101378. https://doi.org/10.1016/j.drup.2026.101378

Vancouver

Wickramasekara R, Jones V, Zhao Y, Luo S, Sun G, Huang RP. Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array–based cytokine profiling. Drug Resistance Updates. 2026;86:101378. doi:10.1016/j.drup.2026.101378

BibTeX
@article{Wickramasekara2026,
  author = {Wickramasekara, Rochelle and Jones, Valerie and Zhao, Yating and Luo, Shuhong and Sun, Guogui and Huang, Ruo-Pan},
  title = {Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array–based cytokine profiling},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {86},
  pages = {101378},
  doi = {10.1016/j.drup.2026.101378}
}
Kostenlos starten →